source
- US biotech faces internal split over reliance on Chinese-developed drug candidatesEd Silverman's Pharmalittle column notes that US biotech firms are wrestling with how to treat Chinese partners, with some seeing them as collaborators and others as competitors. The column highli…
- Regeneron's LAG-3 inhibitor fianlimab fails Phase 3 skin cancer trialRegeneron announced that its experimental LAG-3 inhibitor fianlimab did not meet its primary endpoint in a late-stage trial for a skin cancer indication. The Phase 3 study was designed to evaluate…